The results indicated there was a significant difference in the survival rate between different risk groups in the ccRCC patients with Nivolumab monotherapy from the CheckMate-025 cohort while there was no significant difference in those treated with Everolimus (a mammalian target of mTOR inhibitor) (Additional file 1: Fig. S1d, e), suggesting that our model is more effective and suitable for anti-PD-1/PD-L1 therapy in the ccRCC patients. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.